Oct 19th, 2022

Featured Science for Monday

Today's Featured Science explores HF, COVID-19 science and post PCI/ACS.

Monday, Nov. 7 | 8-9 a.m. | Main Event II

Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (NIHP) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours
A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial (BETA3LVH)
The Prelieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis (Prelieve)
Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (BREXIT) Study (BREXIT)
Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD Into Standard Patient Evaluations (I-DECIDE-LVAD)
STRONG-HF: Successful Post-Discharge Management of Heart Failure (STRONG-HF)

Monday, Nov. 7 | 8-9 a.m. | Main Event III

Anti-C5a Vilobelimab Reduces All-Cause Mortality in Critically Ill COVID-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study (PANAMO)
A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (FERMIN)
Impact of Coronavirus Disease-2019 on Participants in Deliver (DELIVER)
Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe COVID-19 and Cardiac Injury (COVID-CARDOGEN)
Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection—14 U.S. States, March 2020-May 2022 (COVID-NET)

Monday, Nov. 7 | 9:30-10:30 a.m. | Main Event III

Long-Term Outcomes of an Invasive Versus Conservative Strategy in Stabilized Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomized Controlled Trial (After Eighty Study)
Long-Term Follow-Up of Aspirin Versus Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study
Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the Twilight -Recurrent Events Sub-Study (TWILIGHT)
Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study (STOP)

Monday, Nov. 7 | 11 a.m.-Noon Main Event II

The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial (DELIVER)
Baseline Characteristics, Outcomes and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER (DELIVER)
Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure (DAPA-HF, DELIVER)
Differences in Clinical Characteristics, Outcomes and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and DELIVER (DAPA-HF, DELIVER)
Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black Versus White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program (EMPEROR-Pooled)
Long-Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure (RAFT)

Monday, Nov. 7 | 11 a.m.-Noon | Main Event III

Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days (BT001 PIVOTAL)
A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual AppLication-Supported ENvironment To INcrease Exercise (VALENTINE) Study (The VALENTINE Study)
Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients [Smart-Breast]: A Randomized Controlled Trial (SMART-BREAST)
A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia (PROMPT-LIPID)
Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest Cts to Improve Statin Rates (NOTIFY-1)

Monday, Nov. 7 | 3-4 p.m. | Main Event III

ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides and Cholesterol in Patients With Mixed Dyslipidemia (ARCHES-2)
ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum ApolipoproteinC3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia (SHASTA-2)
Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (FOURIER-OLE)
Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial
Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy